Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3243326rdf:typepubmed:Citationlld:pubmed
pubmed-article:3243326lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:3243326lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:3243326lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:3243326lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:3243326lifeskim:mentionsumls-concept:C0006463lld:lifeskim
pubmed-article:3243326lifeskim:mentionsumls-concept:C0280606lld:lifeskim
pubmed-article:3243326lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:3243326lifeskim:mentionsumls-concept:C0412467lld:lifeskim
pubmed-article:3243326pubmed:issue4lld:pubmed
pubmed-article:3243326pubmed:dateCreated1989-6-5lld:pubmed
pubmed-article:3243326pubmed:abstractTextBusulfan kinetics were studied in the rat plasma and brain after an I.P. dose of 14C-busulfan or busulfan (15 mg/kg). The distribution of busulfan to the brain was rapid and the ratio brain/plasma concentration was 0.74 during the time-course of busulfan. The elimination half-lives in plasma and brain were 3h for intact busulfan and 8h for the 14C-radioactivity. The radioactivity remaining in plasma and brain after 24h was mostly busulfan metabolites e.g. sulfolane, 3-hydroxysulfolane and tetrahydrothiophene-1-oxide as identified by gas chromatography-mass spectrometry. The protein binding to rat plasma was low (9.2 +/- 4.4%).lld:pubmed
pubmed-article:3243326pubmed:languageenglld:pubmed
pubmed-article:3243326pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3243326pubmed:citationSubsetIMlld:pubmed
pubmed-article:3243326pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3243326pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3243326pubmed:statusMEDLINElld:pubmed
pubmed-article:3243326pubmed:issn0378-7966lld:pubmed
pubmed-article:3243326pubmed:authorpubmed-author:EhrssonHHlld:pubmed
pubmed-article:3243326pubmed:authorpubmed-author:WallisRRlld:pubmed
pubmed-article:3243326pubmed:authorpubmed-author:HassanMMlld:pubmed
pubmed-article:3243326pubmed:authorpubmed-author:EksborgSSlld:pubmed
pubmed-article:3243326pubmed:issnTypePrintlld:pubmed
pubmed-article:3243326pubmed:volume13lld:pubmed
pubmed-article:3243326pubmed:ownerNLMlld:pubmed
pubmed-article:3243326pubmed:authorsCompleteYlld:pubmed
pubmed-article:3243326pubmed:pagination301-5lld:pubmed
pubmed-article:3243326pubmed:dateRevised2011-2-2lld:pubmed
pubmed-article:3243326pubmed:meshHeadingpubmed-meshheading:3243326-...lld:pubmed
pubmed-article:3243326pubmed:meshHeadingpubmed-meshheading:3243326-...lld:pubmed
pubmed-article:3243326pubmed:meshHeadingpubmed-meshheading:3243326-...lld:pubmed
pubmed-article:3243326pubmed:meshHeadingpubmed-meshheading:3243326-...lld:pubmed
pubmed-article:3243326pubmed:meshHeadingpubmed-meshheading:3243326-...lld:pubmed
pubmed-article:3243326pubmed:meshHeadingpubmed-meshheading:3243326-...lld:pubmed
pubmed-article:3243326pubmed:meshHeadingpubmed-meshheading:3243326-...lld:pubmed
pubmed-article:3243326pubmed:meshHeadingpubmed-meshheading:3243326-...lld:pubmed
pubmed-article:3243326pubmed:articleTitlePharmacokinetic and metabolic studies of busulfan in rat plasma and brain.lld:pubmed
pubmed-article:3243326pubmed:affiliationKarolinska Pharmacy, Stockholm, Sweden.lld:pubmed
pubmed-article:3243326pubmed:publicationTypeJournal Articlelld:pubmed